Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 39, 2012, Pages 15930-15935

  Cannon, Ronald E ^a   Peart, John C ^a,b   Hawkins, Brian T ^c   Campos, Christopher R ^a   Miller, David S ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

ABC transporters; ABCB1; Brain endothelium; Breast cancer related protein; Chemotherapy; Multidrug resistance associated protein

Indexed keywords

FINGOLIMOD; FTY 720P; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN CAPILLARY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG TRANSPORT; IN VIVO STUDY; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; CALCIUM CHANNEL BLOCKERS; CAPILLARIES; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LYSOPHOSPHOLIPIDS; NERVE TISSUE PROTEINS; ORGANOPHOSPHATES; P-GLYCOPROTEIN; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SPHINGOSINE; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA; VERAPAMIL;

RATTUS;

EID: 84866844026     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1203534109     Document Type: Article

References (44)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37:13-25.
2. Miller DS (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31:246-254.
3. Fellner S, et al. (2002) Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309-1318. (Pubitemid 35285757)
4. Ferry DR, Traunecker H, Kerr DJ (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A:1070-1081.
5. Krishna R, St-Louis M, Mayer LD (2000) Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer 85:131-141.
6. Liang XJ, Aszalos A (2006) Multidrug transporters as drug targets. Curr Drug Targets 7:911-921.
7. Killestein J, Rudick RA, Polman CH (2011) Oral treatment for multiple sclerosis. Lancet Neurol 10:1026-1034.
8. Bauer B, et al. (2006) In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70:1212-1219. (Pubitemid 44435972)
9. Hartz AM, Bauer B, Fricker G, Miller DS (2004) Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. Mol Pharmacol 66:387-394. (Pubitemid 39329237)
10. Wang X, Hawkins BT, Miller DS (2011) Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J 25:644-652.
11. Wang X, Sykes DB, Miller DS (2010) Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol 78:376-383.
12. Hartz AM, Bauer B, Fricker G, Miller DS (2006) Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol 69:462-470. (Pubitemid 43121943)
13. Rigor RR, Hawkins BT, Miller DS (2010) Activation of PKC isoform beta(I) at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. J Cereb Blood Flow Metab 30:1373-1383.
14. Xia P, Wang L, Gamble JR, Vadas MA (1999) Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J Biol Chem 274:34499-34505. (Pubitemid 129511798)
15. De Palma C, Meacci E, Perrotta C, Bruni P, Clementi E (2006) Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: A novel pathway relevant to the pathophysiology of endothelium. Arterioscler Thromb Vasc Biol 26: 99-105. (Pubitemid 43732234)
16. Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S (2010) Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 688:141-155.
17. Bauer B, et al. (2008) Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. J Cereb Blood Flow Metab 28:1222-1234. (Pubitemid 351733346)
18. Hartz AM, Mahringer A, Miller DS, Bauer B (2010) 17-β-Estradiol: A powerful modulatorof blood-brain barrier BCRP activity. J Cereb Blood Flow Metab 30:1742-1755.
19. Mitra P, et al. (2006) Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 103:16394-16399. (Pubitemid 44715207)
20. Tanfin Z, Serrano-Sanchez M, Leiber D (2011) ATP-binding cassette ABCC1 is involved in the release of sphingosine 1-phosphate from rat uterine leiomyoma ELT3 cells and late pregnant rat myometrium. Cell Signal 23:1997-2004.
21. Spiegel S, Milstien S (2011) The outs and the ins of sphingosine-1- phosphate in immunity. Nat Rev Immunol 11:403-415.
22. Pfeilschifter W, Czech B, Neumann-Haefelin T (2010) Targeting the sphingolipid signaling pathway in stroke. Stroke, 41:e193; author reply e194.
23. Cohen JA, Chun J (2011) Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 69:759-777.
24. Choi JW, et al. (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 108:751-756.
25. Hawkins BT, Sykes DB, Miller DS (2010) Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 30:1417-1425.
26. Bauer B, Hartz AM, Miller DS (2007) Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 71:667-675. (Pubitemid 46294078)
27. ElAli A, Hermann DM (2010) Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain. Sci Signal 3:ra72.
28. Hartz AM, Bauer B, Block ML, Hong JS, Miller DS (2008) Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier. FASEB J 22:2723-2733.
29. Bauer B, et al. (2008) Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 73: 1444-1453. (Pubitemid 351574834)
30. Wang X, Hawkins BT, Miller DS (2011) Activating PKC-β1 at the blood-brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS. J Cereb Blood Flow Metab 31:1371-1375.
31. Honig SM, et al. (2003) FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest 111:627-637. (Pubitemid 36278581)
32. Pilorget A, et al. (2007) Modulation of P-glycoprotein function by sphingosine kinase-1 in brain endothelial cells. J Neurochem 100:1203-1210.
33. Calabria AR, Shusta EV (2008) A genomic comparison of in vivo and in vitro brain microvascular endothelial cells. J Cereb Blood Flow Metab 28:135-148.
34. Hawkins BT, Rigor RR, Miller DS (2010) Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. J Cereb Blood Flow Metab 30:1593-1597.
35. Edwards LJ, Constantinescu CS (2009) Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases. Inflamm Allergy Drug Targets 8:182-190.
36. Raggers RJ, Vogels I, van Meer G (2001) Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem J 357:859-865. (Pubitemid 32735167)
37. Ernest S, Bello-Reuss E (1999) Secretion of platelet-activating factor is mediated by MDR1 P-glycoprotein in cultured human mesangial cells. J Am Soc Nephrol 10: 2306-2313. (Pubitemid 29501463)
38. Rodrigues DH, et al. (2011) Absence of PAF receptor alters cellular infiltrate but not rolling and adhesion of leukocytes in experimental autoimmune encephalomyelitis. Brain Res 1385:298-306.
39. Callea L, et al. (1999) Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 94: 212-221. (Pubitemid 29071262)
40. Kooij G, et al. (2009) P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS ONE 4:e8212.
41. Kooij G, et al. (2010) T lymphocytes impair P-glycoprotein function during neuroinflammation. J Autoimmun 34:416-425.
42. Dagenais C, Zong J, Ducharme J, Pollack GM (2001) Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm Res 18:957-963. (Pubitemid 32799940)
43. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461. (Pubitemid 37013212)
44. David OJ, Kovarik JM, Schmouder RL (2012) Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet 51:15-28.